O	0	5	Phase
O	6	9	III
O	9	10	,
O	11	22	multicenter
O	22	23	,
O	24	34	randomized
O	35	40	trial
O	41	43	of
B-intervention	44	55	maintenance
I-intervention	56	68	chemotherapy
O	69	75	versus
B-control	76	87	observation
O	88	90	in
O	91	99	patients
O	100	104	with
O	105	115	metastatic
O	116	122	breast
O	123	129	cancer
O	130	135	after
O	136	145	achieving
O	146	153	disease
O	154	161	control
O	162	166	with
O	167	170	six
O	171	177	cycles
O	178	180	of
O	181	192	gemcitabine
O	193	197	plus
O	198	208	paclitaxel
O	209	211	as
O	212	217	first
O	217	218	-
O	218	222	line
O	223	235	chemotherapy
O	235	236	:
O	237	241	KCSG
O	241	242	-
O	242	246	BR07
O	246	247	-
O	247	249	02
O	249	250	.

O	251	254	The
O	255	262	primary
O	263	270	purpose
O	271	273	of
O	274	277	our
O	278	283	study
O	284	287	was
O	288	290	to
O	291	299	evaluate
O	300	307	whether
O	308	319	maintenance
O	320	332	chemotherapy
O	333	337	with
O	338	348	paclitaxel
O	348	349	/
O	349	360	gemcitabine
O	361	362	(
O	362	364	PG
O	364	365	)
O	366	369	was
O	370	378	superior
O	379	381	to
O	382	393	observation
O	394	396	in
O	397	406	improving
O	407	418	progression
O	418	419	-
O	419	423	free
O	424	432	survival
O	433	434	(
O	434	437	PFS
O	437	438	)
O	439	441	in
O	442	450	patients
O	451	455	with
O	456	466	metastatic
O	467	473	breast
O	474	480	cancer
O	481	482	(
O	482	485	MBC
O	485	486	)
O	487	490	who
O	491	499	achieved
O	500	507	disease
O	508	515	control
O	516	520	with
O	521	523	an
O	524	531	initial
O	532	535	six
O	536	542	cycles
O	543	545	of
O	546	548	PG
O	549	551	as
O	552	557	their
O	558	563	first
O	563	564	-
O	564	568	line
O	569	578	treatment
O	578	579	.

O	580	583	The
O	584	589	study
O	590	593	was
O	594	595	a
O	596	607	prospective
O	607	608	,
O	609	619	randomized
O	619	620	,
O	621	632	multicenter
O	632	633	,
O	634	639	phase
O	640	643	III
O	644	649	trial
O	649	650	.

B-eligibility	651	659	Patients
I-eligibility	660	663	MBC
I-eligibility	664	668	with
I-eligibility	669	672	who
I-eligibility	673	681	achieved
I-eligibility	682	689	disease
I-eligibility	690	697	control
I-eligibility	698	703	after
I-eligibility	704	707	six
I-eligibility	708	714	cycles
I-eligibility	715	717	of
I-eligibility	718	720	PG
I-eligibility	721	733	chemotherapy
O	734	738	were
O	739	747	randomly
O	748	756	assigned
O	757	759	to
O	760	771	maintenance
O	772	784	chemotherapy
O	785	787	or
O	788	799	observation
O	800	805	until
O	806	817	progression
O	817	818	.

O	819	821	Of
B-total-participants	822	825	324
O	826	834	patients
O	835	839	from
O	840	842	10
O	843	850	centers
O	851	859	enrolled
O	859	860	,
B-total-participants	861	864	231
O	865	873	patients
O	874	878	with
O	879	882	MBC
O	883	892	exhibited
O	893	900	disease
O	901	908	control
O	909	910	(
O	910	918	complete
O	919	927	response
O	928	929	+
O	930	937	partial
O	938	946	response
O	947	948	+
O	949	955	stable
O	956	963	disease
O	963	964	)
O	965	969	with
O	970	975	first
O	975	976	-
O	976	980	line
O	981	983	PG
O	984	987	and
O	988	992	were
O	993	1001	randomly
O	1002	1010	assigned
O	1011	1013	to
O	1014	1025	maintenance
O	1026	1038	chemotherapy
O	1039	1040	(
O	1040	1041	n
O	1042	1043	=
B-intervention-participants	1044	1047	116
O	1047	1048	)
O	1049	1051	or
O	1052	1063	observation
O	1064	1065	(
O	1065	1066	n
O	1067	1068	=
B-control-participants	1069	1072	115
O	1072	1073	)
O	1073	1074	.

O	1075	1078	The
O	1079	1085	median
O	1086	1089	age
O	1090	1093	was
B-age	1094	1096	48
I-age	1097	1102	years
O	1103	1104	(
O	1104	1109	range
O	1109	1110	,
O	1111	1113	28
O	1114	1116	to
O	1117	1119	76
O	1120	1125	years
O	1125	1126	)
O	1126	1127	,
O	1128	1134	median
O	1135	1141	follow
O	1141	1142	-
O	1142	1144	up
O	1145	1148	was
O	1149	1151	33
O	1152	1158	months
O	1158	1159	,
O	1160	1163	and
O	1164	1170	median
O	1171	1177	number
O	1178	1180	of
O	1181	1193	chemotherapy
O	1194	1200	cycles
O	1201	1203	in
O	1204	1207	the
O	1208	1219	maintenance
O	1220	1225	group
O	1226	1231	after
O	1232	1238	random
O	1239	1249	assignment
O	1250	1253	was
O	1254	1257	six
O	1257	1258	.

O	1259	1262	The
B-outcome	1263	1269	median
I-outcome	1270	1273	PFS
I-outcome	1274	1278	time
O	1279	1284	after
O	1285	1291	random
O	1292	1302	assignment
O	1303	1306	was
O	1307	1313	longer
O	1314	1316	in
O	1317	1320	the
O	1321	1332	maintenance
O	1333	1338	group
O	1339	1343	than
O	1344	1346	in
O	1347	1350	the
O	1351	1362	observation
O	1363	1368	group
O	1369	1370	(
B-iv-cont-median	1370	1371	7
I-iv-cont-median	1371	1372	.
I-iv-cont-median	1372	1373	5
O	1374	1375	v
B-cv-cont-median	1376	1377	3
I-cv-cont-median	1377	1378	.
I-cv-cont-median	1378	1379	8
I-cv-cont-median	1380	1386	months
O	1386	1387	,
O	1388	1400	respectively
O	1400	1401	;
O	1402	1403	P
O	1404	1405	=
O	1406	1407	.
O	1407	1410	026
O	1410	1411	)
O	1411	1412	.

O	1413	1416	The
B-outcome	1417	1423	median
I-outcome	1424	1431	overall
I-outcome	1432	1440	survival
I-outcome	1441	1442	(
I-outcome	1442	1444	OS
I-outcome	1444	1445	)
I-outcome	1446	1450	time
O	1451	1454	was
O	1455	1461	longer
O	1462	1464	in
O	1465	1468	the
O	1469	1480	maintenance
O	1481	1486	group
O	1487	1491	than
O	1492	1494	in
O	1495	1498	the
O	1499	1510	observation
O	1511	1516	group
O	1517	1518	(
B-iv-cont-median	1518	1520	32
I-iv-cont-median	1520	1521	.
I-iv-cont-median	1521	1522	3
O	1523	1524	v
B-cv-cont-median	1525	1527	23
I-cv-cont-median	1527	1528	.
I-cv-cont-median	1528	1529	5
I-cv-cont-median	1530	1536	months
O	1536	1537	,
O	1538	1550	respectively
O	1550	1551	;
O	1552	1553	P
O	1554	1555	=
O	1556	1557	.
O	1557	1560	047
O	1560	1561	)
O	1561	1562	.

O	1563	1566	The
B-outcome	1567	1571	rate
I-outcome	1572	1574	of
I-outcome	1575	1580	grade
I-outcome	1581	1582	3
I-outcome	1583	1585	or
I-outcome	1586	1592	higher
I-outcome	1593	1604	neutropenia
O	1605	1610	after
O	1611	1617	random
O	1618	1628	assignment
O	1629	1632	was
O	1633	1639	higher
O	1640	1642	in
O	1643	1646	the
O	1647	1658	maintenance
O	1659	1664	group
O	1665	1669	than
O	1670	1672	in
O	1673	1676	the
O	1677	1688	observation
O	1689	1694	group
O	1695	1696	(
B-iv-bin-percent	1696	1698	61
I-iv-bin-percent	1698	1699	%
O	1700	1701	v
B-cv-bin-percent	1702	1703	0
I-cv-bin-percent	1703	1704	.
I-cv-bin-percent	1704	1705	9
I-cv-bin-percent	1705	1706	%
O	1706	1707	,
O	1708	1720	respectively
O	1720	1721	;
O	1722	1723	P
O	1724	1725	<
O	1726	1727	.
O	1727	1730	001
O	1730	1731	)
O	1731	1732	.

O	1733	1735	In
O	1736	1744	patients
O	1745	1749	with
O	1750	1753	MBC
O	1754	1757	who
O	1758	1766	achieved
O	1767	1774	disease
O	1775	1782	control
O	1783	1787	with
O	1788	1790	an
O	1791	1798	initial
O	1799	1802	six
O	1803	1809	cycles
O	1810	1812	of
O	1813	1815	PG
O	1816	1828	chemotherapy
O	1828	1829	,
O	1830	1841	maintenance
O	1842	1844	PG
O	1845	1857	chemotherapy
O	1858	1866	resulted
O	1867	1869	in
O	1870	1876	better
O	1877	1880	PFS
O	1881	1884	and
O	1885	1887	OS
O	1888	1896	compared
O	1897	1901	with
O	1902	1913	observation
O	1913	1914	.
